Fagron completed the acquisition of Fresenius Kabi.

Fagron, a pharmaceutical compounding company, completed the acquisition of Fresenius Kabi, a healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Financial terms were not disclosed. “This acquisition is an important step for us in realizing our strategic objective of becoming the leading global platform for sterile outsourcing services. The demand for outsourced compounding is increasing in the US and aligned to increased regulatory scrutiny necessitates a high focus on quality. Whilst this acquisition will initially be dilutive, we are confident our team will successfully bring the facility in line with our FSS US operations in due course. This expansion will allow us to elevate our US sterile compounding business to the next level and compete with the top-3 players in the US market.” Rafael Padilla, Fagron CEO.